Wall Street Outlook For Elevance Health, Inc. (ELV) Supported By Prior TD Cowen Upgrade

Group 1 - Elevance Health, Inc. (NYSE:ELV) is considered a cheap healthcare stock with a median price target of $394, indicating an upside potential of 19.12% [1] - TD Cowen raised the price target for Elevance Health to $400 from $380, maintaining a 'Buy' rating and highlighting it as their "Best Idea for 2026" [2] - Mizuho reduced its price target for Elevance Health to $400 from $420 while keeping an 'Outperform' rating, also lowering earnings guidance for 2026 and 2027 due to challenges in Carelon [3] Group 2 - Elevance Health operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other, and aims to simplify the healthcare system [4]